FARMINGDALE, N.Y., March 16, 2011 /PRNewswire/ — Misonix, Inc.
(Nasdaq:
MSON), a medical device company that designs, manufactures, and
markets innovative, therapeutic, ultrasonic products worldwide for
wound debridement, spinal surgery, cosmetic surgery, neurosurgery,
laparoscopic surgery, and other surgical and medical applications,
has announced a definitive agreement for non-exclusive
distribution, with the exception of certain selected accounts, of
the BoneScalpel Ultrasonic Bone Cutting System in the United States
with Aesculap, Inc., which replaces a prior exclusive distribution
agreement between the parties. The agreement is limited to
clinical applications relative to the spine and cranium.
In response, Misonix will begin the marketing, sales,
distribution and service of the BoneScalpel in the U.S., effective
immediately, utilizing its 75 person surgical sales organization,
which markets direct to hospitals and free-standing surgery
centers. In addition to spine and cranial applications, the
Misonix sales organization will market the product for a broad
range of maxiofacial and other small bone clinical
applications.
The BoneScalpel is a tissue specific osteotomy device capable of
making precise cuts through bone and hard tissue while largely
preserving delicate soft tissue structures. It offers the
convenience and speed of a power instrument while minimizing the
peril associated with rotary sharps.
“Misonix is excited about adding BoneScalpel to our focused,
domestic sales organization. With this Agreement, Misonix
will now be selling the BoneScalpel worldwide,” said Michael A.
McManus, Jr., President and Chief Executive Officer of Misonix.
“Over time, we anticipate significant margin improvement and
sales growth by allowing our proprietary sales organization the
opportunity to sell another one of our key products under t
‘/>”/>
SOURCE
